Volume 28, Number 2—February 2022
Research Letter
Antenatal Seroprevalence of Zika and Chikungunya Viruses, Kingston Metropolitan Area, Jamaica, 2017–2019
Table
Virus, clinic | Tested, no. | Result |
|||
---|---|---|---|---|---|
Negative, no. | Equivocal, no. | Positive, no. (%) |
|||
Chikungunya* | |||||
A | 54 | 11 | 4 | 39 (72.2) | |
B | 159 | 19 | 0 | 140 (88.1) | |
C | 76 | 8 | 2 | 66 (86.8) | |
D | 197 | 34 | 5 | 158 (80.2) | |
E | 98 | 9 | 4 | 85 (86.7) | |
Total |
584 |
81 |
15 |
488 (83.6) |
|
Zika† | |||||
A | 54 | 44 | 0 | 10 (18.5) | |
B | 159 | 138 | 1 | 20 (12.6) | |
C | 76 | 64 | 1 | 11 (14.5) | |
D | 197 | 166 | 3 | 28 (14.2) | |
E | 98 | 75 | 1 | 22 (22.4) | |
Total | 584 | 487 | 6 | 91 (15.6) |
*Euroimmun CHIKV IgG ELISA (https://www.euroimmun.com). †BLACKBOX ZIKV IgG ELISA (https://www.bnitm.de).
1Preliminary results from this study were presented at the 2nd International Conference on Zika Virus and Aedes Related Infections; June 14–17, 2018; Tallinn, Estonia.
2Members of the ZIKAction Consortium are listed at the end of this article.
Page created: December 02, 2021
Page updated: January 23, 2022
Page reviewed: January 23, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.